S Kant Healthcare Limited Naproxen Export Data — India (DGFT 2022–2026)

Name: S Kant Healthcare Limited Naproxen Export Records India — #15 Exporter, 36 Shipments, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Naproxen

India Pharmaceutical Trade Intelligence

$133.8M192 Suppliers76 CountriesHS 30049069

ExportsIndia → UNITED STATES42.1%India → CANADA21.1%

ImportsUNITED STATES → India$391.7K GERMANY → India$185.0K

#1 Supplier: MYLAN LABORATORIES #1 Buyer: MYLAN PHARMACEUTICALS

S Kant Healthcare Limited — Naproxen Exporter #15 | $1.6M Trade Value | TransData Nexus | TransData Nexus

S Kant Healthcare Limited — Naproxen Exporter Profile

Indian Pharmaceutical Exporter · #15 for Naproxen · $1.6M export value · DGFT Verified

S Kant Healthcare Limited is the #15 Indian exporter of Naproxen with $1.6M in export value and 36 verified shipments. S Kant Healthcare Limited holds a 1.2% market share in Naproxen exports across 1 countries. The company exports 12 pharmaceutical products worth $35.0M across 6 therapeutic categories.

S Kant Healthcare Limited — Naproxen Export Profile: Buyers & Destinations

S Kant Healthcare Limited Naproxen export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Naproxen?

Country	Value	Shipments	Share
UNITED STATES	$46.1M	923	50.5%
SLOVENIA	$13.8M	276	15.1%
MALTA	$8.6M	528	9.5%
CANADA	$6.5M	129	7.1%

Who Are the Top Buyers of Naproxen from India?

Buyer	Country	Value	Orders
GLENMARK PHARMACEUTICALS INC., USA	UNITED STATES	$11.0M	231
KRKA D.D., NOVO MESTO	SLOVENIA	$6.3M	126
APL SWIFT SERVICES (MALTA) LTD.,	MALTA	$5.2M	291
ATNAHS PHARMA UK LIMITED	SPAIN	$5.1M	156
AMNEAL PHARMACEUTICALS, LLC (KY)	UNITED STATES	$4.1M	82
TIME-CAP LABS,	UNITED STATES	$3.6M	90
KRKA D D NOVO MESTO	SLOVENIA	$2.8M	56
KRKA, D.D., NOVO MESTO	SLOVENIA	$2.7M	54
DR REDDYS LABORATORIES INC	UNITED STATES	$1.1M	23
MYLAN PHARMACEUTICALS ULC,	CANADA	$350.0K	7

India's Naproxen is purchased by 366 buyers worldwide. The top buyer is GLENMARK PHARMACEUTICALS INC., USA (UNITED STATES), followed by KRKA D.D., NOVO MESTO and APL SWIFT SERVICES (MALTA) LTD.,.

How Does S Kant Healthcare Limited Compare to Nearest Naproxen Exporters?

Exporters ranked immediately above and below #15 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
13	FOURRTS I LABORATORIES PRIVATE LIMITED	$1.9M	47	2	$41.3K
14	MEDREICH LIMITED	$1.9M	101	4	$18.8K
15	S KANT HEALTHCARE LIMITED ★	$1.6M	36	1	$45.7K
12	DR REDDYS LABORATORIES LIMITED	$900.0K	18	1	$50.0K

S Kant Healthcare Limited ranks #15 among 192 Indian Naproxen exporters. Average shipment value of $45.7K compared to the market average of $405.2K. The closest competitors by value are FOURRTS I LABORATORIES PRIVATE LIMITED and MEDREICH LIMITED.

Which Indian Ports Ship Naproxen Exports?

Port	Shipments	% Share
NHAVA SHEVA SEA (INNSA1)	429	12.6%
SAHAR AIR CARGO ACC (INBOM4)	245	7.2%
SAHAR AIR	236	6.9%
DELHI AIR CARGO ACC (INDEL4)	211	6.2%
JNPT/ NHAVA SHEVA SEA	156	4.6%
HYDERABAD ICD	145	4.2%
VIZAG SEA	140	4.1%
BANGALORE AIR	128	3.7%

Geopolitical & Trade Policy Impact on S Kant Healthcare Limited's Naproxen Exports

Recent geopolitical developments have introduced challenges and opportunities for Indian pharmaceutical exporters like S Kant Healthcare. The escalation of tensions in the Red Sea region, including Houthi attacks, has led to increased shipping costs and extended transit times for Europe-bound shipments. Major carriers have rerouted vessels around the Cape of Good Hope, adding 10–20 days to transit and raising freight rates by 40–50% on key India–Europe routes. Given that approximately 80% of India's exports to Europe traverse the Red Sea, these disruptions could significantly impact S Kant Healthcare's logistics and cost structures. (livemint.com)

Conversely, the India–European Union Free Trade Agreement (FTA), concluded on January 27, 2026, aims to liberalize trade and investment between the two economies. The agreement is expected to eliminate tariffs on most European pharmaceutical imports, potentially enhancing market access for Indian exporters. However, compliance with the EU's stringent regulatory standards, such as the Falsified Medicines Directive, remains a critical factor for market entry. (en.wikipedia.org)

In the United States, the imposition of tariffs on pharmaceutical imports poses a potential risk. While Indian generics have traditionally entered the U.S. duty-free, any changes in import policies could affect profitability. Additionally, the U.S. emphasis on reshoring pharmaceutical manufacturing may alter demand dynamics, necessitating strategic adjustments by exporters like S Kant Healthcare. (cfo.economictimes.indiatimes.com)

S Kant Healthcare Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent Good Manufacturing Practice (GMP) requirements. Historical instances of non-compliance have led to import bans and reputational damage for Indian firms. Therefore, S Kant Healthcare must maintain rigorous quality control systems to ensure uninterrupted market access.

The EU's Falsified Medicines Directive mandates comprehensive verification of pharmaceutical products, including serialization and traceability measures. Adherence to these regulations is essential for exporting to European markets. Additionally, the India–EU FTA may introduce new compliance frameworks, necessitating proactive adaptation by exporters. (en.wikipedia.org)

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Naproxen shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: S Kant Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 76+ countries, 366+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Naproxen

Naproxen

S Kant Healthcare Limited — Naproxen Exporter Profile

S Kant Healthcare Limited — Naproxen Export Profile: Buyers & Destinations

Where Does India Export Naproxen?

Who Are the Top Buyers of Naproxen from India?

What Is India's Total Naproxen Export Value and How Much Does S Kant Healthcare Limited Contribute?

What Is the Average Shipment Value for S Kant Healthcare Limited's Naproxen Exports?

How Does S Kant Healthcare Limited Compare to Other Indian Naproxen Exporters?

Regulatory Requirements: Exporting Naproxen to Key Markets

United States — FDA

Canada — HC

How Does S Kant Healthcare Limited Compare to Nearest Naproxen Exporters?

Which Indian Ports Ship Naproxen Exports?

Geopolitical & Trade Policy Impact on S Kant Healthcare Limited's Naproxen Exports

S Kant Healthcare Limited — Regulatory Compliance & Quality Standards

About S Kant Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Naproxen Export Data from S Kant Healthcare Limited

Naproxen Stats

Company Overview

Top Products by S Kant Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source